DSpace Fukushima Medical University

福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.68 (2022) >

Please use this identifier to cite or link to this item: http://ir.fmu.ac.jp/dspace/handle/123456789/1935

Files in This Item:

File Description SizeFormat
FksmJMedSci_68_p191.pdf768.64 kBAdobe PDFDownload
Title: Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report
Authors: Kojima, Manabu
Soeda, Shu
Okabe, Chikako
Sato, Tetsu
Kamo, Norihito
Ueda, Makiko
Endo, Yuta
Nomura, Shinji
Tokuda, Emi
Furukawa, Shigenori
Kataoka, Masao
Fujita, Shotaro
Saji, Shigehira
Watanabe, Takafumi
Fujimori, Keiya
Affiliation: 産科婦人科学講座
Source title: Fukushima Journal of Medical Science
Volume: 68
Issue: 3
Start page: 191
End page: 195
Issue Date: 2022
Abstract: Surgery can be curative treatment for pelvic locoregional recurrence of endometrial cancer; however, a cure is contingent on complete resection. Here, we report the case of a patient in whom recurrent endometrial tumor remained in the pelvis after resection; long-term control was achieved with postoperative administration of pembrolizumab.The patient had recurrent endometrial cancer of stage IA and was treated with chemotherapy and radiation, but tumor persisted in the pelvic cavity. We therefore attempted total pelvic exenteration, but the tumor was adherent to the pelvic wall and complete resection could not be achieved. However, postoperative administration of pembrolizumab controlled the residual tumor for more than two years without regrowth. We believe that since the resected tumor was MSI-High, the residual tumor responded well to pembrolizumab. It is not known whether cytoreductive surgery contributes to a long-term response to pembrolizumab, but at least in our patient, pembrolizumab appeared to be a very effective drug therapy for MSI-High endometrial cancer that was refractory to chemotherapy and radiotherapy.
Publisher: The Fukushima Society of Medical Science
Publisher (Alternative foam): 福島医学会
language: eng
URI: http://ir.fmu.ac.jp/dspace/handle/123456789/1935
Full text URL: http://ir.fmu.ac.jp/dspace/bitstream/123456789/1935/1/FksmJMedSci_68_p191.pdf
ISSN: 0016-2590
DOI: 10.5387/fms.2022-10
PubMed ID: 36351631
Related Page: https://doi.org/10.5387/fms.2022-10
Rights: © 2022 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.
Rights: https://creativecommons.org/licenses/by-nc-sa/4.0/
Appears in Collections:Vol.68 (2022)

Files in This Item:

File Description SizeFormat
FksmJMedSci_68_p191.pdf768.64 kBAdobe PDFDownload

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard